Intuitive's
da Vinci 5 surgical system has received a CE mark for use in adult cardiac surgery in Europe, including coronary artery bypass procedures. The approval gives the company a regulatory foundation to expand its presence in minimally invasive cardiac surgery, after a long period during which it reduced its focus on this market.
A return to a field where expansion was delayed
The first cardiac procedures using da Vinci systems date back to 1998 in France and Germany, but Intuitive said that technical limitations in its first-generation platforms led it to shift its attention toward other procedures that achieved broader adoption. The company believes that the current capabilities of da Vinci 5 enable it to rebuild its cardiac surgery initiative on a larger scale.
Intuitive plans to work with global cardiac associations to develop training pathways, and it will also collaborate with a limited number of European centers to establish repeatable cardiac surgery programs before expanding their scope. The company is also focusing on generating the clinical evidence needed to support these programs.
What changes in practice?
The design of da Vinci 5 allows surgeons to perform operations through small incisions instead of opening the sternum, according to the company. Intuitive will provide new instruments specifically designed for cardiac procedures, along with a dedicated customer-support infrastructure, according to Dirk Barten, the company's chief commercial officer in Europe.
The move is not limited to the European market. Earlier this year, da Vinci 5 received authorization from the U.S. Food and Drug Administration for use in nine cardiac procedures, including mitral and tricuspid valve repair, mitral valve replacement, and left atrial appendage closure.
Why does this news matter?
Cardiovascular disease is the leading cause of death globally, making cardiac surgery a significant commercial and clinical opportunity for medical-device companies. Jamie Samath, Intuitive's chief financial officer, said during a second-quarter earnings call that cardiac procedures are among the key long-term opportunities the company is anticipating.
However, expansion will not depend on regulatory approval alone. The company needs to train surgeons, build clinical evidence, and demonstrate the ability to operate consistent programs across multiple centers. The announcement also comes at a time when Intuitive experienced an unexpected slowdown in procedure growth in the United States during the second quarter, adding a strategic dimension to the attempt to open a new area of growth.
Editorial reading: The actual change is the transition of da Vinci 5 from limited cardiac approvals to an attempt to establish a complete European ecosystem for robotic cardiac surgery, including instruments, training, and operational infrastructure. The source does not yet establish the scale of clinical adoption or patient outcomes broadly; therefore, clinical evidence and the ability of centers to replicate the programs will remain two decisive factors in determining whether the approval translates into actual adoption.